<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748785</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-IMJ-001</org_study_id>
    <nct_id>NCT02748785</nct_id>
  </id_info>
  <brief_title>MTX Discontinuation and Vaccine Response</brief_title>
  <official_title>Effect of Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether a short term discontinuation of methotrexate (MTX) will improve the
      vaccination efficacy to seasonal influenza vaccination without deteriorating RA disease
      activity in a randomized clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects the joints
      as the main target of the inflammation. Patients with RA require chronic treatment with
      disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX), which
      constitutes the mainstay of treatment.

      Underlying immune dysfunction and the additional immune suppression associated with treatment
      render patients with RA more susceptible to infection. Thus, vaccination against preventable
      diseases including influenza, pneumococcal pneumonia and hepatitis B is recommended for all
      RA patients who are subject to treatment with immunesupprssive drugs, unless there is a
      contraindication to the use of vaccination. However, low dose of glucocorticoids,
      conventional DMARDs and biological DMARDs including tumor necrosis factor inhibitors have
      been reported to substantially decrease vaccine response (4); MTX has been reported to be
      associated with a decreased response to seasonal influenza vaccination by up to 15%.

      To optimize a vaccine response, vaccination should be administrated before the treatment with
      immunesuppressive medications is initiated. However, most patients with RA are already on
      stable dose of DMARDs at the time of when vaccinations, especially vaccine against seasonal
      influenza that needs annual administration, are considered. Alternatively, temporarily
      discontinuation of DMARDs might restore normal immune response to and so improve the efficacy
      of vaccination.

      Although a short term discontinuation of DMARDs during perioperative period has not been
      associated with increased disease activity the longer discontinuation of DMARDs might lead to
      a significant aggravation of RA disease activity. To optimize the vaccine response, a short
      term discontinuation of DMARDs could be considered if this approach proves to be safe and
      effective.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfactory Vaccination Responses Against 3 Antigens</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfactory Vaccination Responses Against &gt; 2/3 Antigens</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfactory Vaccination Responses Against &gt; 1/3 Antigens</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Seroprotection Against H1N1</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seroprotection is defined as antibody titers of ≥40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Seroprotection Against H3N2</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seroprotection is defined as antibody titers of ≥40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Seroprotection Against B-Yamagata</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seroprotection is defined as antibody titers of ≥40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Antibody Titer Against H1N1</measure>
    <time_frame>Day of and 4 weeks after vaccination</time_frame>
    <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Antibody Titer Against H3N2</measure>
    <time_frame>Day of and 4 weeks after vaccination</time_frame>
    <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Antibody Titer Against B-Yamagata</measure>
    <time_frame>Day of and 4 weeks after vaccination</time_frame>
    <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 Flare Rate at Visit 4</measure>
    <time_frame>20 weeks from enrollment.</time_frame>
    <description>DAS28 flare rate at visit 4 as compared to visit 1. RA flare was defined as an increase in DAS28 of &gt;1.2 (or &gt;0.6 if the baseline DAS28 was ≥3.2).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Group 1 (No MTX Hold before Vaccination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will continue MTX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (MTX hold 4 Weeks before vaccination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (MTX hold 2 Weeks before Vaccination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (MTX hold on Day of Vaccination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be continued</description>
    <arm_group_label>Group 1 (No MTX Hold before Vaccination)</arm_group_label>
    <arm_group_label>Group 2 (MTX hold 4 Weeks before vaccination)</arm_group_label>
    <arm_group_label>Group 3 (MTX hold 2 Weeks before Vaccination)</arm_group_label>
    <arm_group_label>Group 4 (MTX hold on Day of Vaccination)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Influenza vaccine</intervention_name>
    <description>all subjects will be vaccinated with a seasonal influenza vaccine</description>
    <arm_group_label>Group 1 (No MTX Hold before Vaccination)</arm_group_label>
    <arm_group_label>Group 2 (MTX hold 4 Weeks before vaccination)</arm_group_label>
    <arm_group_label>Group 3 (MTX hold 2 Weeks before Vaccination)</arm_group_label>
    <arm_group_label>Group 4 (MTX hold on Day of Vaccination)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females &gt; 18 years at time of consent

          -  Have a diagnosis of RA per ACR criteria

          -  Must understand and voluntarily sign an informed consent form including writing
             consent for data protection

          -  Stable doses of methotrexate over the preceding 6 weeks

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Previous anaphylactic response to vaccine components or to egg.

          -  Acute infection with T &gt;38°C at the time of vaccination

          -  History of Guillain-Barre syndrome or demyelinating syndromes

          -  Previous vaccination with any live vaccine 4 weeks before or any inactivated vaccine 2
             weeks before the study

          -  Blood transfusion within 6 months

          -  Active rheumatoid arthritis necessitating a recent change in the drug regimen

          -  Any other rheumatic disease such as systemic lupus erythematosus, mixed connective
             tissue disease, dermatomyositis/polymyositis, and vasculitis except for secondary
             Sjogren's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287-93.</citation>
    <PMID>12355475</PMID>
  </reference>
  <reference>
    <citation>McMahan ZH, Bingham CO 3rd. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther. 2014 Dec 23;16(6):506. doi: 10.1186/s13075-014-0506-0. Review.</citation>
    <PMID>25587634</PMID>
  </reference>
  <reference>
    <citation>Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20.</citation>
    <PMID>25795907</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <results_first_submitted>December 30, 2016</results_first_submitted>
  <results_first_submitted_qc>November 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2018</results_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eun Bong Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Visit 1- Visit 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Visit 2-Visit 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Visit 3- Visit 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.1" spread="13.1"/>
                    <measurement group_id="B2" value="58.5" spread="113.3"/>
                    <measurement group_id="B3" value="58.1" spread="10.9"/>
                    <measurement group_id="B4" value="58.1" spread="11.7"/>
                    <measurement group_id="B5" value="58.5" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="4.5"/>
                    <measurement group_id="B2" value="6.1" spread="4.9"/>
                    <measurement group_id="B3" value="4.9" spread="4.4"/>
                    <measurement group_id="B4" value="6.2" spread="5.5"/>
                    <measurement group_id="B5" value="6.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score (DAS)-28</title>
          <description>The Disease Activity Score (DAS) is a combined index to measure the disease activity in patients with Rheumatoid Arthritis (RA).
The DAS will provide a number between 0 and 10, indicating how active the rheumatoid arthritis is at this moment, whereas a higher values represent a worse disease activity.
0.. minimum score 10..maximum score</description>
          <units>units on a scale (0-10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="1.1"/>
                    <measurement group_id="B2" value="2.8" spread="1.2"/>
                    <measurement group_id="B3" value="2.6" spread="1.0"/>
                    <measurement group_id="B4" value="2.6" spread="1.0"/>
                    <measurement group_id="B5" value="2.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Satisfactory Vaccination Responses Against 3 Antigens</title>
        <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
        <time_frame>8 weeks</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfactory Vaccination Responses Against 3 Antigens</title>
          <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
          <population>Per Protocol</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Seroprotection Against H1N1</title>
        <description>Seroprotection is defined as antibody titers of ≥40</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Seroprotection Against H1N1</title>
          <description>Seroprotection is defined as antibody titers of ≥40</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Seroprotection Against H3N2</title>
        <description>Seroprotection is defined as antibody titers of ≥40</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Seroprotection Against H3N2</title>
          <description>Seroprotection is defined as antibody titers of ≥40</description>
          <units>percentage of patients w/ seroprotection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Seroprotection Against B-Yamagata</title>
        <description>Seroprotection is defined as antibody titers of ≥40</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Seroprotection Against B-Yamagata</title>
          <description>Seroprotection is defined as antibody titers of ≥40</description>
          <units>percentage of patients w/ seroprotection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Antibody Titer Against H1N1</title>
        <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
        <time_frame>Day of and 4 weeks after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Antibody Titer Against H1N1</title>
          <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.4" upper_limit="7.8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.2" upper_limit="7.8"/>
                    <measurement group_id="O3" value="8.7" lower_limit="5.3" upper_limit="14.5"/>
                    <measurement group_id="O4" value="8.1" lower_limit="5.3" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Antibody Titer Against H3N2</title>
        <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
        <time_frame>Day of and 4 weeks after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Antibody Titer Against H3N2</title>
          <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="4.3" upper_limit="8.1"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.4" upper_limit="8.5"/>
                    <measurement group_id="O3" value="12.2" lower_limit="8.4" upper_limit="17.5"/>
                    <measurement group_id="O4" value="10.0" lower_limit="6.8" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Antibody Titer Against B-Yamagata</title>
        <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
        <time_frame>Day of and 4 weeks after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Antibody Titer Against B-Yamagata</title>
          <description>Fold change = post-vaccination titer/pre-vaccination titer</description>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.1" upper_limit="3.7"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.3" upper_limit="6.7"/>
                    <measurement group_id="O4" value="6.1" lower_limit="4.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28 Flare Rate at Visit 4</title>
        <description>DAS28 flare rate at visit 4 as compared to visit 1. RA flare was defined as an increase in DAS28 of &gt;1.2 (or &gt;0.6 if the baseline DAS28 was ≥3.2).</description>
        <time_frame>20 weeks from enrollment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28 Flare Rate at Visit 4</title>
          <description>DAS28 flare rate at visit 4 as compared to visit 1. RA flare was defined as an increase in DAS28 of &gt;1.2 (or &gt;0.6 if the baseline DAS28 was ≥3.2).</description>
          <units>percentage of flare patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="19.1"/>
                    <measurement group_id="O4" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Satisfactory Vaccination Responses Against &gt; 2/3 Antigens</title>
        <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
        <time_frame>8 weeks</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfactory Vaccination Responses Against &gt; 2/3 Antigens</title>
          <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
          <population>Per Protocol</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="52.3"/>
                    <measurement group_id="O3" value="71.4"/>
                    <measurement group_id="O4" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Satisfactory Vaccination Responses Against &gt; 1/3 Antigens</title>
        <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
        <time_frame>8 weeks</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfactory Vaccination Responses Against &gt; 1/3 Antigens</title>
          <description>Seroresponse is defined as serconversion or ≥4-fold increase in antibody titers</description>
          <population>Per Protocol</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="81.8"/>
                    <measurement group_id="O3" value="87.8"/>
                    <measurement group_id="O4" value="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At each visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Group 1 will continue MTX
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
Methotrexate: Methotrexate will be continued
Seasonal Influenza vaccine: all subjects will be vaccinated with a seasonal influenza vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eun Bong Lee</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>+82-2-2072-4399</phone>
      <email>leb7616@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

